Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Therapy in Diabetic Kidney Disease
NCT07039318Phase 2Completed
- Sponsor
- National Institute of Blood and Marrow Transplant
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic kidney disease (DKD) comparing Mesenchymal stem cells with Normal Saline (Placebo) (2 arms). Primary endpoint: Glomerular Filtration Rate at 6 months. Started Dec 2022; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT07039318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07039318.